The combination of anti-NF-κB agents and immune checkpoint inhibitors, although having great potential to treat various cancers, especially treatment resistant and rapidly progressing types, will still face many questions concerning mechanisms of action and possible adverse effects. This evidence concerns the gene NFKB1 and cancer.